MPN-specific oncogene mutations such as JAK2V617F and MPLW515L stimulate the JAK/STAT3 pathway to enhance inflammatory cytokine production by autocrine and paracrine mechanisms, promoting the growth of the other MPN cells but suppressing the growth of normal cells. This evidence concerns the gene STAT3 and myeloproliferative disorder.